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Sequencing of human genomes extracted from
single cancer cells isolated in a valveless
microfluidic device†
Rodolphe Marie, *a Marie Pødenphant,‡a Kamila Koprowska,‡b Loic Bærlocher,‡c
Roland C. M. Vulders,‡d Jennifer Wilding,b Neil Ashley,b Simon J. McGowan,b
Dianne van Strijp,d Freek van Hemert,d Tom Olesen,e Niels Agersnap,e
Brian Bilenberg,f Celine Sabatel,g Julien Schira,c Anders Kristensen,a
Walter Bodmer,b Pieter J. van der Zaag d and Kalim U. Mirh
Sequencing the genomes of individual cells enables the direct determination of genetic heterogeneity
amongst cells within a population. We have developed an injection-moulded valveless microfluidic device
in which single cells from colorectal cancer derived cell lines (LS174T, LS180 and RKO) and fresh colorectal
tumors have been individually trapped, their genomes extracted and prepared for sequencing using multi-
ple displacement amplification (MDA). Ninety nine percent of the DNA sequences obtained mapped to a
reference human genome, indicating that there was effectively no contamination of these samples from
non-human sources. In addition, most of the reads are correctly paired, with a low percentage of single-
tons (0.17 ± 0.06%) and we obtain genome coverages approaching 90%. To achieve this high quality, our
device design and process shows that amplification can be conducted in microliter volumes as long as the
lysis is in sub-nanoliter volumes. Our data thus demonstrates that high quality whole genome sequencing
of single cells can be achieved using a relatively simple, inexpensive and scalable device. Detection of ge-
netic heterogeneity at the single cell level, as we have demonstrated for freshly obtained single cancer
cells, could soon become available as a clinical tool to precisely match treatment with the properties of a
patient's own tumor.
1 Introduction
Standard molecular methods that analyse DNA sequences in
populations of cells need sufficiently deep sequencing to de-
tect heterogeneity at any given location of the genome and do
not clearly define the co-occurrence of mutations in a given
cell, and so do not define precisely the genetic heterogeneity
in a tissue, especially cancers. Cancers arise from a somatic
evolutionary process in which mutations, or relatively stable
epigenetic changes, are successively selected for and therefore
occur with relatively high frequency in the population of can-
cer cells. It is these genetic and epigenetic changes that deter-
mine the properties of a cancer and so are the major determi-
nants of prognosis and of the responses to different
treatments. With the extraordinary development of DNA se-
quencing technology, there is now extensive data on the types
and frequencies of the major, so called ‘driver’, mutations
found in a wide variety of cancers, and in some cases very
clear evidence of the relationship between the mutational
content of a cancer, and its response to therapy. As a result,
there is now great interest in DNA sequencing of single can-
cer cells to determine the nature and extent of clonal genetic
heterogeneity in a given cancer.
Treatment can then be directed at the different clones that
co-exist in the cancer and thus single cell DNA sequencing1
becomes an extremely important tool for matching the treat-
ment of a cancer to its genetic make up. This is the essence
of precision medicine as applied to cancer treatment. There
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is also an interest in single cell mRNA analysis,2 which can
help to identify gene expression differences, due mainly to
DNA methylation as well as interest in examining methyla-
tion directly.3,4 There has therefore been increasing focus on
the development of methods that obtain molecular informa-
tion from single cells by isolating and sequencing their DNA
and mRNA content.5–7 Similarly, in metagenomics, where
bacteria, fungi and other microbes may not be culturable, a
robust single cell analysis is important to evaluate the ge-
nomes of the distinct microbes present in a sample.8 In addi-
tion to untangling heterogeneity, the single cell methods are
relevant to cases when only a small number of cells is avail-
able, for example in the analysis of circulating tumour
cells9,10 and circulating fetal cells in maternal blood.11 A sin-
gle diploid human cell contains around 7 picograms of geno-
mic DNA and some form of amplification is therefore needed
to obtain the amounts of material necessary for current se-
quencing methods. Amplification by multiple displacement
amplification (MDA)12 and PCR based methods such as DOP-
PCR,13 Picoplex14 and, multiple annealing and looping-based
amplification cycles (MALBAC)15 have been used relatively ef-
fectively to do single cell whole genome DNA sequencing. Ge-
nome coverage of >90% has been claimed to be routinely
obtained from single cells using MDA and MALBAC, with a
MDA kit adapted for single cells reportedly giving superior all
round performance.13 However, issues around uniformity of
coverage, allelic dropout, false positives (amplification and/or
sequencing errors) and unmappable reads (e.g. from primer-
dimers), remain.16
The MDA process results in uneven coverage across the ge-
nome. Some of the amplification biases are presumed to be a
result of stochastic effects due to the sampling of a small
number of molecules. In MALBAC amplification bias can be
corrected by normalizing the GC content.17 Another approach
to dealing with this problem is the use of barcoding or iden-
tification tags.18–20
Contamination, if not carefully controlled can lead to diffi-
culty in interpreting results and limits the sequencing capac-
ity that is available for a single cell of interest. To combat
this, single cell genomics is preferably conducted in a clean
room,16 in microwells,21 or in a microfluidic device.8,12,17
Contamination can also be assessed by the use of appropriate
known genetic markers. Using a microfluidic device provides
the containment of cells and their immediate lysis products,
and the controlled amplification within the device limits the
loss of material when handling small volumes.
Existing microfluidic devices8,17 requiring multiple-PDMS
layers,22 one layer for the passage of fluids and another for
valves to control the fluids through the device, are difficult
and expensive to manufacture because PDMS casting is not a
scalable industrial process. We introduce a novel valve-less
microfluidic device for single cell genomics that is
manufactured in a thermoplastic material by injection
moulding, a process that is scalable at low cost.23 Our chip
design is based on a hydrodynamic cell trap24 derived from a
previously described device for cell culture.25 Our device de-
sign enables the process to be carried out on an optical
microscope or in “Cell-O-Matic” a specially built single cell
processing instrument (Philips BioCell), in either case
allowing us to monitor both cell trapping and genome
extraction.
Our single cell sequencing data obtained using the Cell-O-
Matic instrument show that we can achieve reasonable levels
of whole genome coverage in a significant proportion of cells.
Our results compare well with other reported whole genome
sequencing from single cells using instrumentation in which
the amplification is performed in nanoliter-reaction cham-
bers. In our device only the DNA extraction occurs in a sub-
nanoliter volume of solution, while the amplification is
performed by adding microliter volumes of reagents in the
device outlet. We conclude that the critical step in single cell
whole genome amplification with regard to sequence allelic
dropout, contamination and genome coverage is to extract
DNA in sub-nanoliter volumes in the confinement of the
microfluidic device, while performing the amplification in
such small volumes may only be required for reduction of re-
agent consumption, but at the cost of higher device complex-
ity and cost.
2 Material and methods
2.1 Device fabrication
The device is fabricated by injection moulding of TOPAS
5013, a cyclic olefin copolymer with a glass temperature of
130 °C, as described elsewhere26 but with some modifica-
tions. First, the microchannel network is defined to have a
depth of 30 μm in a silicon substrate by UV lithography and
reactive ion etching. All dimensions of the microchannel net-
work can be found in Fig. S1a–f.† Next, a Ni/V seed layer is
deposited on the silicon master and nickel is electroplated at
a final thickness of 300 μm. Silicon is removed by KOH etch-
ing. The nickel shim is cut to fit in the mould of the injection
moulder (Engel, Germany). The mould creates a 2 mm-thick,
50 mm diameter disc replica of the shim and 12 holes
through the disc used to connect the microfluidics. It also
creates for each hole, a female LUER connector on the side
opposite the microfluidics side. The temperature of the
mould is regulated such that injection moulding is
performed using a variotherm process27 allowing the polymer
part to be moulded and removed from the mould at different
temperatures. The shim is replicated using a mould tempera-
ture of 115 °C, a shim temperature of 155 °C, a holding pres-
sure of 1150 bar and a cooling time of 14 seconds so the
demoulding temperature is below 126 °C. The microfluidics
chips are sealed with a 150 μm-thick TOPAS 5015 foil using
UV assisted thermal bonding. The initial roughness of the
foil is reduced by a hot embossing process on a hydraulic
press (P/O/Weber, Germany) at 140 °C and 5.1 MPa using two
smooth nickel discs electroplated from silicon wafers. The
glass transition temperature (Tg) of TOPAS 5013 is 130 °C.
The devices and lids are exposed to UV-light from a mercury
arc lamp for 30 s and then placed in an aluminium holder
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that fits to the LUER fittings. A smooth nickel disc and a thin
PDMS plate are placed on top of the lid to ensure a uniform
pressure across the device during bonding at 125 °C and 1.5
MPa for 3 minutes.
2.2 Instrument
The microfluidic device can either be mounted on a conven-
tional epi-fluorescence microscope or on a custom designed in-
strument. The instrument is a modified Philips BioCell
Fluidscope7 (Fig. S1g and S2†). In brief, the single use micro-
fluidic chip is mounted on a stage equipped with translation
(y-axis) as well as temperature control via three Peltier ele-
ments. The temperature inside the wells of the chip is cali-
brated and regulated by a proportional–integral–derivative
(PID) controller using the temperature of the stage as input.
The lid closing the microfluidic chip wells is connected to a
multi-channel pressure controller (MFCS-EZ, 300 mbar range,
Fluigent). The chip is imaged using an objective (10×, NA 0.45
Wild Heerbrugg) mounted on a translation stage (x-axis) and
focusing by z-translation. Epi-fluorescence imaging is
performed with an excitation at 470 nm (LED, Thorlabs model
M470L3) equipped with collimator lenses. A dual band filter
cube (Semrock, excitation filter model 733-495/605-Di01-25 ×
36, dichroic mirror model 733-474/23-25, emission filter model
733-527/645-25) allows imaging of green fluorescence and
bright field. The bright-field illuminator delivers light from the
top side of the device through a window in the lid using a LED
with center wavelength of 505 nm and a 20 nm bandwidth. A
CMOS imaging sensor (Fairchild, CIS1910) with 1920 × 1080
pixels, and pixel size 6.5 μm, is used with a home-built image
board. Finally, all the elements are controlled through software
which guides the user through a pre-established workflow for
priming, cell capture, lysis and amplification.
2.3 Device operation (see Protocol S3† for the detailed
operation procedure)
Solutions are pipetted into the LUER connectors used as reser-
voirs containing up to 50 μL of solution. Air pressure supplied
by the pressure controller attached to the wells drives the flow
inside the device. We apply pressure to the cell inlet as well as
the buffer inlets B1 and B2 (Fig. 1) while the waste and the
trap outlets are always left at atmospheric pressure. For cell
capture, pressures in the range of 5 to 10 mbar were applied,
corresponding to sample flow rates of 2.9–5.7 μL h−1. Details
of the pressure settings used are given in the Protocol S3.†
2.4 Wet lab
The colorectal cell lines used in this study were provided by
the Department of Oncology located at the Weatherall Insti-
tute of Molecular Medicine (Oxford). Experiments were
conducted across two sites, Oxford and Eindhoven where the
LS174T, LS180 and RKO cells were maintained in the same
fashion. Briefly, the LS174T and LS180 cells were cultured in
DMEM (Gibco, Life Technologies). RKO was cultured in RPMI
(Gibco, Life Technologies) and all media were supplemented
with 10% fetal bovine serum (FBS), (Gibco, Life Technolo-
gies), 2 mM Glutamax (Gibco Life Technologies), 1% penicil-
lin/streptomycin (Gibco, Life Technologies). Cells were grown
at 37 °C in a humidified incubator containing 10% CO2 in
air. When cells reached sub-confluency they were routinely
passaged 2–3 times per week via dissociation with 0.25%
trypsin containing 0.04% EDTA (Gibco, Life Technologies)
upon two rinse steps with phosphate buffered saline (PBS)
(Gibco, Life Technologies). In addition the cells were periodi-
cally tested for Mycoplasma spp. infection (Agilent 302107).
Cells from colorectal cancer cell lines LS174T, LS180 or
RKO (concentration: 6 × 105 cells per mL) were stained with 1
mM calcein AM and suspended in BD FACSFlow buffer
(Becton Dickinson). After cell capture, the trap occupancy
was checked by bright field and fluorescence imaging of the
calcein signal. After trapping cells, the B1 and B2 inlets were
emptied leaving negligible volumes in the outlets.
2.4.1 On-chip protocol 1: (39 cells, processed in Oxford).
The devices were primed with degassed 0.1% v/v Triton X-100
in BD FACSFlow buffer (1 minute at 200 mbar) followed by
degassed 0.1 mg mL−1 bovine serum albumin (BSA) (Sigma)
in BD FACSFlow buffered (2 minutes at 200 mbar). The cell
suspensions were loaded onto the chip and cells were
trapped (see Protocol S3†). The alkaline lysis buffer of a com-
mercial MDA kit was used to lyse the trapped cells (REPLI-g
UltraFast Mini Kit, Qiagen). The lysates were pushed with 20
μL of the alkaline lysis buffer, incubated for 20 minutes at
room temperature, and then pushed with 20 μL of the
neutralisation buffer for 20 minutes at room temperature (for
further details see Protocol S3†).
2.4.2 On chip protocol 2: (13 cells, processed in Eindho-
ven). In a second experiment, we processed cells in a differ-
ent laboratory using a different cell lysis protocol based on
proteolysis. The protocol is essentially the same as protocol 1
with a few modifications. The device was primed with etha-
nol (Fisher Scientific) from all inlets (cells, B1 and B2) then
BD FACSFlow buffer was loaded in all wells before cells were
loaded. In all the samples, the cell cytosol is removed by a
Fig. 1 Device design and operation. (a) Image of the single use
polymer device. Scale bar is 1 cm. (b) Microfluidics layout. (c)
Conditions for cell trapping an unoccupied trap r < rc. (d) The trapped
cell reduces the flow through the trap such that for the next incoming
cell, r > rc. (e–g) Flow directions in the device under priming, cell
capture and lysis.
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solution of 0.5% Triton-X100 in 0.5× Tris borate EDTA
(TBE) buffer (Sigma), containing 1 μM of YOYO-1 dye
(ThermoFisher Scientific).7 The DNA was extracted from the
cells by proteolysis buffer containing >200 μg mL−1 protein-
ase K (Qiagen), 0.5% v/v Triton-X100 in 0.5× TBE buffer. Then
alkaline lysis solution from the REPLI-g single cell kit was
added to the outlet well.7
2.4.3 Whole genome amplification in device outlets.
Whole genome amplification (WGA) was performed using
REPLI-g single cell or the Qiagen REPLI-g UltraFast Mini Kit
(Qiagen) which are based on multiple displacement amplifi-
cation (MDA) technology to amplify gDNA from small sam-
ples. 10 μL of reaction mix with Phi29 polymerase was added
to the chip outlets containing gDNA. The device was left on
the heated stage of the instrument (alternatively placed in a
thermal cycler) for 8 hours at 30 °C. The final step was 5 min
at 65 °C to inactivate the polymerase. All WGA steps were
done on chip. Following this the amplified DNA was trans-
ferred to PCR tubes, tested for quality and, subject to passing
quality control, sent to Fasteris for library preparation and
DNA sequencing.
2.4.4 Multiplex chromosome check at Oxford (off-chip). To
confirm the quality of WGA products, multiplex PCR was
performed.§ Five primers targeting 5 chromosomes (2, 4, 12,
13 and 22) were used. PCR products (295 bp Chr13, 235 bp
Chr12, 196 bp Chr2, 150 bp Chr22 and 132 bp Chr4) were vi-
sualized on a 4% agarose gel (see Protocol S3†).¶
2.5 Library preparation and sequencing
Samples for sequencing were quantified using a Qubit fluo-
rometer instrument before starting the library preparation
procedure. Depending on the initial sample concentration,
the library preparation was done using the Illumina Nextera
or the Illumina Nextera XT kits. Sequencing reactions were
performed for all samples using Illumina HiSeq technology
as 2 × 125 base pairs high-output runs.
2.6 Bioinformatics
All libraries sequenced were then mapped against the human
genome GRCh37. We report on the percentage of reads
mapped to the human genome (Fig. 2a) and the total number
of reads (Fig. 2b). We also use the cumulative fraction of ba-
ses covered to generate Lorenz plots (Fig. 3) and the coverage
plots (Fig. 4). For all samples, allelic dropout estimates
(Fig. 5 and 6) were based on a set of validated heterozygous
variants, selected for each cell line: 12 single nucleotide poly-
morphisms (SNPs) were used for the LS174T and LS180 cells,
13 for the RKO cells (see Table S2†). The known variants were
searched for in the raw variant results, namely without apply-
ing any filter on the variant quality. All selected variants were
correctly detected in the respective bulk samples as heterozy-
gous variants. For single cells, a drop of a heterozygous vari-
ant to a homozygous call would reflect dropout of a single al-
lele, while absence of any call would represent a dropout of
both alleles (resulting in no coverage of the position). The
procedure used for generating Fig. 5 and 6 is described in de-
tail in the Results section. From the Lorenz and the coverage
plot we calculate the Gini coefficient G and the evenness
score E respectively. For the latter, the normalized coverage
curve is used and scaled by the maximum fraction of genome
covered in a bulk sequencing run of 10/9.136. This is done to
account for the fact that in the bulk sequencing of LS174T,
8.36% of the bases remain uncovered.7
§ See http://www.sigmaaldrich.com/technical-documents/articles/life-science-in-
novations/qualitative-multiplex.html.
¶ These 5 positions were chosen based on https://www.sigmaaldrich.com/
technical-documents/articles/biology/ffpe-wga-poster.html.
Fig. 2 Read metrics. a) Percentage of mapped reads and b) total
number of reads. Legend displays the mean, the standard deviation
and the standard error of the mean (s.e.m).
Fig. 3 Lorenz plots for the cells processed by alkaline lysis in Oxford,
in three groups of n = 13 cells: (a) bottom, (b) middle and (c) top
tercile according to the percentage of non-covered bases in the ge-
nome. (d) Lorenz plot for the single cells processed by proteolysis in
Eindhoven, n = 13 cells. Cells 124 to 236 are LS174T cells. Cells 335 to
343 are RKO cells. The bulk of LS174T is also shown (sample ID 46).
We display the Gini coefficient G mean value and the standard devia-
tion for each group.
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3 Results
We mainly used the LS174T cell line derived from a colorec-
tal cancer (CRC) as a model system for single cell analysis.
This is a very well characterized cell line (see e.g. ref. 28) that
has been widely used for CRC cell characterization and drug
response studies (see e.g. ref. 29 and 30). In some experi-
ments, we also processed cells from the RKO and LS180 cell
lines (the latter was alternatively derived from the same CRC
as LS174T), and from cells obtained directly from fresh
CRCs.
For each experiment a single use microfluidic device
(Fig. 1a and S1†) is placed in the instrument allowing bright
field and fluorescence imaging, the control of the device tem-
perature and connection of the device inlets (cell, B1 and B2
inlet, Fig. 1b) to a multi-channel air pressure controller7 (Fig.
S1g†). Fluorescence imaging and the use of YOYO-1 interca-
lating DNA dye enabled monitoring of cell lysis. However, the
dye may be omitted to avoid interference with the subsequent
quality of the preparations with respect to their use for DNA,
or RNA sequencing.7
Fig. 4 Coverage plots corresponding to the (a) bottom, (b) middle and
(c) top tercile and (d) the single cells processed by proteolysis in
Eindhoven. Cells 124 to 236 are LS174T cells. Cells 335 to 343 are RKO
cells. The bulk of LS174T is also shown (sample ID 46). We display the
E-score as mean value and the standard deviation for each group. The
E-score is calculated from a normalized coverage curve as described
in ref. 36.
Fig. 5 Extent of allelic dropout for 12 heterozygous SNPs selected for LS174T (36 cells) and LS180 cells (3 cells). On the x-axis, the sample ID for
the cells analyzed. Cells are ordered by increasing p-value (in percent). The mean (SD) for all 39 cells processed in Oxford is 60 (25).
Fig. 6 Extent of allelic dropout for heterozygous SNPs for cells
processed in Eindhoven. Cells 124 to 236 are LS174T cells (12
heterozygous SNPs) and cells 335 to 343 are RKO cells (13
heterozygous SNPs).
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3.1 Device design and fabrication
The microfluidic device is a single use passive device fabri-
cated by injection moulding using a mould that creates 12
connectors placed at distances corresponding to a 96-well
plate standard and can contain up to 50 μL of a solution26
(Fig. 1b). The microfluidic device has a single depth micro-
channel network with dimensions such that LS174T and sim-
ilar colorectal epithelial cells are successfully transported and
trapped (Fig. S4†). LS174T cells have a median diameter of 14
μm, which is in the characteristic size range for colorectal
cancer cells, and so we designed the microfluidic network to
be 30 μm-deep and at least 30 μm-wide except for the flow
constrictions that are used as cell traps.
Our design is the result of iterative optimization where we
identified and improved three critical aspects of the device
design and fabrication: i) the flow through the trap, which
depends on its cross section and the flow resistance of the
outlet channels, ii) the shape of the cell pocket and iii) the
moulding quality of the cell inlet.
The trap cross section has to be smaller than the LS174T
cells size to retain the cells, but also sufficiently large so that
it collects a significant fraction of the main flow in the feed-
ing channel for cells to be directed through the trap. As a
boundary condition, our choice of a single depth design
means that the trap depth remains the same throughout the
chip, namely 30 μm. As a result, the trap has a high aspect
ratio, within the limit achievable during the fabrication of
the master in silicon by micromachining. Finally, the fabrica-
tion by polymer replication results in the channels and in
particular the trap having tilted sidewalls (up to 3 degrees) to
allow the separation of the polymer part from the mould dur-
ing injection moulding. As a result, the cell traps have a cross
section 30 μm-deep, 4.5 μm wide at the bottom and 7.5 μm
wide at the top. The pocket receiving the cell has an asym-
metric design (Fig. 1c and d). This is in contrast to previously
reported devices based on hydrodynamic trapping where flow
focusing is used to direct the cell to a microfluidic constric-
tion that is a bypass in an otherwise symmetric flow profile.
In our device, the flow focusing is asymmetric since cells are
aligned against the wall of the feeding channel. A symmetric
pocket creates a dead volume after the constriction (Fig. S4†)
that is a spot where a cell decelerates and can settle just out-
side the cell trap. By making the pocket asymmetrical, we im-
prove the flow profile such that cell trapping is more effi-
cient. The optimized design gave the best results in terms of
numbers of traps per chip having single cells.
Finally, the connection of the feeding channel and the
well receiving the cells is a critical aspect of the design. The
surface roughness at the inlet is of paramount importance
since a sharp edge tends to stop cells entering the channel.
The injection moulding parameters are therefore adjusted to
produce a round edge. In addition, we ensured that the shim
is mounted into the injection moulder only once. This greatly
improved the quality of the final device since successive
mounting of the shim increases the roughness at the connec-
tions with the inlets due to the alignment tolerance of the
shim in the mould. On the optimized device (Fig. 1), single
cells were trapped routinely, on average, in 3 to 6 out of 8 pos-
sible traps. On rare occasions, cell doublets are trapped and
this may be because cell doublets enter the device in the first
place. For this reason, cell traps are imaged in bright field
and fluorescence after trapping to confirm the presence of,
and then exclude, such cell doublets from further analysis.
3.2 Cell capture and lysis
For each experiment, solutions are loaded in the device
wells and a single pressure is applied to the inlets either to
wet the device, trap cells or lyse the trapped cells (Fig. 1e–g
and Protocol S3†). After priming of the microfluidics, cells
loaded in a cell inlet are pushed into the feeding channel
where they become aligned against a sidewall of the chan-
nel by the incoming flow from the buffer inlets (B1 and B2
in Fig. 1b), similarly to a recently described cell-trapping
device.31 Once aligned, a cell of radius r follows a stream-
line at a distance r from the sidewall. The cell traps are
constrictions that connect the feeding channel with sepa-
rate outlets. A trap collects a fraction of the flow from the
feeding channel such that we call rc the position of the last
streamline entering the trap. A cell of radius r enters the
trap downstream if r < rc (Fig. 1c). Since a trap is only 4.5
μm-wide, a cell entering it is captured in the constriction.
This cell then occupies a pocket recessed from the main
flow through the feeding channel. A cell cannot block the
flow through the trap completely since the channel depth
(30 μm) is much larger than the cell. However, the flow re-
sistance is sufficiently increased for the next incoming cells
to pass by and be directed to the following free trap
(Fig. 1d). Cells that are not trapped are collected in the
waste outlet.
Cellular DNA is eluted from the cell trap by introducing a
lysis solution from the inlet B1 (Fig. 1b). In our study, we
compared two lysis solutions. For one, a solution for proteoly-
sis including proteinase K and Triton-X100 was used for the
13 cells (LS174T and RKO) whose results were obtained in
Eindhoven. This lysis solution enables collecting the RNA
prior to collecting the DNA of the trapped cell.7 Alternatively,
an alkaline lysis buffer (D2, pH above 12) provided with the
Repli-g UltraFast kit was used in Oxford for the analysis of the
39 single cells from the LS174T and LS180 cell lines, and from
two fresh tumour samples (Fig. S4†). The alkaline lysis is the
one adopted in commercially available kits for eluting DNA
for sequencing. Both solutions successfully lyse the cells
trapped and elute the DNA from the trap as observed in exper-
iments where the DNA is labelled with an intercalating dye so
it can be visualized by fluorescence microscopy. From the re-
sults of the single cell sequencing using the two different ap-
proaches, as discussed below, we conclude that both ap-
proaches to lysis were appropriate for MDA. This is, perhaps,
surprising in the case of DNA extraction by proteolysis since
proteinase K might be expected to digest the polymerase.
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However, there are six orders of magnitude difference be-
tween the volumes of lysate (pL) and the volumes of the re-
agents added to the well (μL), which thus makes the protease
content in the MDA mix insignificant.7 The success of the am-
plification and sequencing is the best indication that the lysis
is successful.
DNA samples that successfully amplified were passed
through a quality control. For the samples processed in Ox-
ford, we PCR amplified five genes from five different chromo-
somes to give five different sized fragments, and visualized
them on an agarose gel (see Protocol S3† for details). Only
samples which successfully displayed at least 4 of the 5 PCR
products were used for library preparation and sequencing. Es-
sentially all of the single cell lysates were successfully ampli-
fied for DNA and more than 90% of the Oxford samples passed
the subsequent quality filter (i.e. quantification by a pico-green
assay (Qubit)) before being passed on for DNA sequencing. For
samples processed in Eindhoven, a quality check comprising
PCR of RNase P was performed on some samples. Next, some
of the samples were then checked by 1) quantification by Qubit
and 2) a test run of sequencing performed at a low number of
reads in order to assess the quality of the library before the ac-
tual sequencing presented in this paper. Sequencing libraries
were successfully prepared from 97% of the samples that
passed the initial quality control.
3.3 Non-human contamination
Fig. 2a shows the percentage of reads that mapped to the ref-
erence genome for 52 cells that were whole genome se-
quenced. Apart from 7 clear outlier cells (<99% mapped
reads), 99% of the DNA sequences obtained mapped to a ref-
erence human genome, indicating that there was effectively
no contamination of these samples from non-human
sources. This is a significant achievement as there are several
published reports of reagent-induced contamination.32–34 In
addition, most of the reads are correctly paired, with a low
percentage of singletons (0.17 ± 0.06%). Libraries prepared
from single cell DNA show very different levels of representa-
tion of the human genome. In the following we summarise
the metrics of our sequencing using Lorenz plots (Fig. 3), cov-
erage plots (Fig. 4) and allelic dropout analysis (Fig. 5 and 6).
For readability we display the alkaline lysis data set in three
terciles where cells are grouped according to their allelic
dropout p-value (Fig. 5). Bad representation of the human ge-
nome may be caused by the loss of DNA in the device as
supported by the fact that increasing the depth of sequencing
for a representative subset of samples did not result in signif-
icantly improved coverage. The distribution of the number of
reads per cell is given in Fig. 2b.
3.4 Coverage
We generated Lorenz plots displaying the fraction of the ge-
nome covered versus the fraction of the reads for 39 cells
processed in Oxford (Fig. 3a–c) and 13 of the single cell se-
quencing sets obtained from the Eindhoven laboratory
(Fig. 3d). There is good agreement between these plots and
the coverage data shown in Fig. 2a. Thus, those plots farthest
from the diagonal are for the cells with the poorest whole ge-
nome coverage. We follow Szulwach et al.35 and calculate G,
the Gini coefficient for the Lorenz plots, to quantify the uni-
formity of the genome coverage. The Gini coefficient G is cal-
culated as:
G = 1 − 2A. (1)
In which A is the area under the Lorenz curve. For an ide-
ally uniform coverage of the genome, the Lorenz plot displays
a diagonal and the area under the curve is 0.5. G = 0 indicates
an ideally uniform coverage of the genome. In our study, G =
0.3 for the sequencing of the bulk of LS174T and many cells
have a G = 0.5 (see Fig. 3d and S5†). In the top tercile of the
cells processed in Oxford, corresponding to the highest cover-
age, G = 0.6 ± 0.1 (n = 13 cells). For comparison, using com-
mercial instrumentation, Szulwach et al. report G = 0.36 ±
0.04 (n = 5) for GM12752 cells where the bulk sequencing
gives a G just below 0.2, but also G = 0.6 for another cell
type.35 Thus far most of the single cell sequencing studies
only report the coverage results using the Lorenz plot.5,6,15,35
Although the Lorenz graph is effective in reporting which
fraction on the genome is not covered, for reporting the dis-
tribution of the coverage the so-called coverage graph is more
suited and used in (bulk) sequencing experiments. Previously
we have reported a coverage graph of single cell sequencing
experiments.7 Here, we report a more complete overview of
the coverage of our results in Fig. 4. The evenness score E:
(2)
in which FĲi) is the fraction of the positions with normalized
coverage of at least C(i)/Cave and Cave is the average coverage
provides a metric to quantify the evenness of a read distribu-
tion.36 This metric has been proposed as one of the 7 metrics
to form a description metric for targeted enrichment experi-
ments.37 Here, we use the E-score to quantify the evenness of
the read distribution in our single cell sequencing experi-
ments. Note that the E-score provides a quantitative metric to
the coverage graph in the same way as the Gini-coefficient
does this for the Lorenz graph. The E-score has been put with
the coverage and rose from a value 29.3 ± 5.9% for the
poorest results in Fig. 4a to around 55–56 ± 10% for our best
results (Fig. 4c and d). Comparing this result to E-scores
found in targeted sequencing experiments of 70 ± 5% (ref.
36) and the E-score of 87.5% in bulk sequencing (Fig. 4d) this
suggests that further optimization of the evenness in the read
distribution and in the first step of the gDNA amplification
process is still needed. Note that the E-score is calculated
from a normalized coverage distribution. These normalized
coverage graphs are shown in Fig. S6.† We show the E-score
per cell in Fig. S7† as well as the coverage graphs in Fig. 4,
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without normalization as this gives a more direct view of the
read distribution.
3.5 Allelic dropout
Next, SNP data were used to obtain estimates of the total re-
covery of genomic DNA taking into account the near diploid
karyotype of LS174T, given that it is mismatch repair defec-
tive (Fig. 5). From bulk DNA sequencing of both LS174T and
LS180 we can easily identify SNPs that are unequivocally
heterozygous in both cell lines and which must represent
germ line heterozygosity in the patient from whose cancer
the two cell lines were derived. Full coverage of the near dip-
loid genome present in LS174T in a single cell sequence
would mean, that for such SNPs, both alleles must always be
present and observed. If, in the presence of incomplete cover-
age, we assume that p is the probability that one allele of the
SNP pair is observed, and that the probability of observing ei-
ther allele is the same, then p2 is the probability of finding
both SNP alleles, 2p(1 − p) is the probability of finding only
one of the alleles, and (1 − p)2 is the probability that neither
allele is found, namely a drop out from both genomes. This
is the same binomial result as represented by the frequencies
of homozygotes and heterozygotes in a random mating popu-
lation according to the Hardy–Weinberg law. If a is the num-
ber of times both alleles are found, b the number of times
one allele is found and c the number of times neither allele
is found then the maximum likelihood estimate of p is:
p = 2a + b/2n. (3)
where n = a + b + c. This estimate uses the information from
all three types of situation rather than just the frequency of
heterozygosity, which is a direct estimate of p2 and ignores
the information contained in the number of times just one
allele is observed. If this calculation is done for a number of
SNPs known to be heterozygous in each single cell, then a, b
and c can be estimated from the aggregated data on the num-
ber of times: a, both alleles for the various SNPs are found in
the single cell's DNA sequence, b, when only one of the al-
leles is found and c, when neither allele is found. The esti-
mate, p, from this aggregate will then be an estimate of the
probability of finding any position of the genome in that
cell's DNA sequence once, and p2 will be the probability that
the DNA from both the genomes at that site should be pres-
ent. Thus, assuming the SNPs are a random sample of points
on the genome both with respect to position and differential
amplification, p2 is an estimate of the true probability of cov-
erage of the total genomic content of the DNA in that singe
cell. This is different from the proportion of sequences that
map to a reference genome, which does not take into account
the presence of two genomes in each cell and so is more or
less an estimate of p rather than p2.
Fig. 5 shows the results of such an analysis for DNA pre-
pared from the single cells in Oxford using a panel of 12
SNPs known to be heterozygous in the LS174T and LS180 cell
lines. The different colours of the vertical bars for each single
cell show the proportions of times 2 : 1 or no alleles are
found, and the cells are ordered from highest to lowest esti-
mate of p. The corresponding Lorenz plots for these DNA se-
quences (Fig. 3a–c) show that there is a reasonable relation-
ship between the coverage estimates from the Lorenz plots
and the p value estimates. About 44% (17/39) of these single
cell DNA sequences give p value estimates of around 0.7 or
more, indicating total genomic coverage per cell of around
50%, while about 25% give total coverage of greater than
70%. The overall average p-value using the data on all 39 sin-
gle cells is 0.60 ± 0.25 corresponding to complete coverage of
just under 40% (the average p value for the Eindhoven data
in Fig. 6 is 0.63 ± 0.22). Out of more than 10 000 reads cover-
ing the 13 pairs of alleles for the SNPs, only 63 were ‘incor-
rect’ in the sense that they were not expected for either allele
pair of a given SNP. This indicates a sequencing error rate of
less than 1% and also the absence of any contaminating hu-
man DNA from external sources, namely other than the cells
being analysed.
Additional evidence for the absence of contamination with
exogenous DNA was obtained from the density of reads that
mapped to male-specific genes on the Y-chromosome, see Ta-
ble S3.† Since both the LS174T and the RKO cell lines are de-
rived from female patients and the operators in the Eindho-
ven laboratory were male, lack of Y chromosome reads
provides evidence that there was at least no contamination of
Y chromosome reads from them. The male-specific genes
used in this analysis are those for which there are no homolo-
gies on the X-chromosome as taken from the work of Page
and co-workers.38 For almost all male-specific genes we found
zero reads mapping to them whereas the mean number of
reads per gene on the X-chromosome (taken over all genes
listed in the Ensemble human genome annotation GTF file) is
over 900 reads per gene on average for these all samples (Ta-
ble S3†). This value is to be compared to average number of
reads found for the male-specific genes which is 0.4 read per
gene (Table S3†). This effectively rules out exogenous DNA
contamination from the male operators in the Eindhoven lab-
oratory to occur and suggests that these reads mapping to
male specific genes found corresponds to amplification, se-
quencing and mapping errors. Since the error rate for se-
quencing on an Illumina HiSeq system is in the order of 1%.
One usually refers to a minimum number of Q30 base (num-
ber of base where the error rate is below 1/1000). For 2 × 125
bp reads of HiSeq, we should have error rate below 1.5% (esti-
mation using an indexed PhiX). The exact value depends on
each run. Our data suggest a mapping error of 0.4/900 =
0.04%.
The heterogeneity of the frequencies of reads (data not
shown) between SNPs within single cells suggests dropping
out, namely absence of DNA in the initial single cell prepara-
tion, as the main reason for lack of complete coverage. Simi-
larly, Fig. 6 gives an estimate of the allelic drop-out for the
single cells processed in Eindhoven for which the Lorenz
graph is shown in Fig. 3d. Note that for the RKO cells, 13
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heterozygous SNPs across the genome where used. Again, the
results are concordant with the measures of coverage and the
Lorenz curves. The poorest cells, with the highest allelic
drop-out are right in the far lower corner of the Lorenz plot
in Fig. 3d, while the best cells, with 60–70% sharing, corre-
spond to the curves nearest to the diagonal. In addition to
the analysis of single cells from the colorectal cancer-derived
cell lines, some single cell whole genome sequences were
obtained directly from two fresh colorectal cancers. These
were analysed following the same procedure described above
using different appropriately chosen sets of SNP markers for
each cancer. The results shown in Fig. S8† for a further total
of 15 single cells demonstrate that at least comparable qual-
ity single cell whole genome DNA sequences can be obtained
from fresh tumours as were obtained from the cell line cul-
tures. Our overall results indicate that the independent analy-
ses of singe cell DNA sequences using two different protocols
in different laboratories, but using the same device and in-
strument, gave comparable results, with perhaps somewhat
better coverage using the protocol with alkaline lysis com-
pared to the protocol using proteolytic lysis. Moreover, the re-
sults obtained using our valve free devices which are simpler
in design and manufacture are comparable with the best
published results. For details of the experimental protocols
and the use of the instrument see the methods section and
the Protocol S3.†
4 Discussion
Experimental omics approaches39,40 to separately process mul-
tiple single cells are increasingly important. Four types of ap-
proaches are available for partitioning the molecular contents
of one cell from another: 1) dilution and separately processing;
2) statistical dilution, tagging and pooling,41 2) droplet,42,43 3)
micro/nanowell,21,44 4) microfluidic trapping.7,8,45–48
We found that sequencing genomic DNA extracted from
single cells inside our low-cost microfluidic device, gave sin-
gle cell DNA sequencing results of comparable quality to
those reported using more complex and expensive instru-
ments. Our device is valve free and can thus be fabricated by
injection moulding a polymer. It is also straightforward and
can be operated on a commercial optical microscope or using
a custom-built instrument, Cell-O-Matic.
Moreover, in this study the cell lysis is performed in the
sub-nanoliter cell trap of the device while the amplification
step is performed in the outlet wells in μL volumes. The rep-
resentation of the genome in the sequencing data is similar
to single cell sequencing obtained in devices where both
DNA extraction and amplification take place in nL volumes.35
In addition, we also show that the genome representation of
single cells processed in the microfluidic device is on average
better than when both cell lysis and amplification are
performed in μL volumes. Here we compare to sequencing of
single cells sorted by FACS in individual PCR tubes and am-
plified using the unmodified MDA protocol, i.e. with an alka-
line lysis (see Fig. S9†). In this case the Gini coefficient is
higher (G = 0.9 ± 0.1, n = 7) and the evenness (E = 24.1 ± 16.9,
n = 7) lower than for the lower tercile of the alkaline lysis
data set (Fig. 3c and 4c). This shows that only the DNA extrac-
tion may be crucial to a good single cell sequencing. The
main reason for a poor representation of the genome may be
the loss of DNA and/or equally the loss of enzymatic activity.
When amplification takes place in confinement of a nano-
liter volume, enzyme may be lost on surfaces due to the high
area-to-volume ratio and this may outbalance the benefit of
maintaining a high template concentration.
Our device design focuses only on DNA extraction thus its
design is not specific to any amplification protocol and the
end-user may be free to implement any other amplification
protocol. Moreover, the device design includes inlet wells
that are placed in a grid matching that of a 96-well plate thus
that standard lab robotics could be used to perform the am-
plification step.
Previously described microfluidic devices isolate single
cells using either a physical valve8 or an oil phase21 at the
time of the lysis and subsequently for the amplification. The
use of valves to trap the cells necessitates two-layer devices
which are complex and hard to manufacture. By contrast, our
devices have no valves and are thus easier to design, manufac-
ture and use. We are able to operate without valves because
the liquid flow from different inlets is strictly controlled by air
pressure with high accuracy. This, in particular, allows us to
exchange reagents in the feeding channel while maintaining
the cells trapped until they need to be lysed. The flow rate is
minimal as too high flows would dislodge the cells from the
traps. The laminar flow conditions in the feeding channel
and through the traps ensure that the lysate is pushed
through the trap. At a later stage, during the amplification,
the solution is confined to the outlet since the loss of material
from the outlet well through diffusion into the microfluidic
channel is negligible (see ESI† and Fig. S10). The design of
the traps, the mode of lysis and collection of the resulting
DNA makes it unlikely that there is significant contamination
between the cells trapped on the same chip. Preliminary data
obtained by analysis of the LS174T cell line, which is a known
mixture of two cell populations (unpublished observations),
suggests that there is no major contamination between
neighbouring traps on the same chip.
A further proof of the absence of contamination between
neighbouring traps can be derived from a subset of data
where mRNA was extracted from the captured cells.7 There,
PCR of the AXIN2 and beta-actin genes was used to assess
the presence of mRNA in the outlet wells. In those experi-
ments, no mRNA was detected from empty traps adjacent to
those where cells were successfully captured and lysed.
Finally, we also consider contamination by exogenous hu-
man DNA. The allele analysis of heterozygous SNPs from
throughout the entire genome shown in Fig. 5 and 6. In this
analysis, we detect only the alleles that we expect for the
LS174T cell line which gives us a good indication that there
is no contamination from extraneous human DNA. In addi-
tion, we also look at the presence of reads mapped to






















































































1900 | Lab Chip, 2018, 18, 1891–1902 This journal is © The Royal Society of Chemistry 2018
Y-chromosome genes knowing that the cell lines used in this
study are female cell lines. Here, we find generally no reads
mapping to those genes (see Table S2†). Some reads do map
to a few Y-chromosome genes such as PCDH11Y for all sam-
ples but we show that this is due to homologies with genes
on the X-chromosome. The density of reads that map to chro-
mosome Y is below 3% and typically 0.05% of the input of a
single cell, so should be attributed to amplification and se-
quencing errors. The absence of exogenous human contami-
nation may be surprising at first since the devices are fabri-
cated in a standard laboratory environment (i.e. not a clean
room environment). The microfluidic chip is injection
molded on an industrial equipment and assembled to a poly-
mer foil. However, the assembly is realised by UV-assisted
thermal bonding. The strong UV illumination during the
bonding of the lid would destroy any foreign DNA before the
microfluidic channels are sealed. Immediately after bonding
the lid, the device connectors are covered by PCR tape.
When comparing our data to previously published DNA
sequencing from single cells we see that the Gini coefficients
(see Fig. 3) are similar to results obtained on a commercial
system.35 Previously7 and here we have shown coverage
graphs of our single-cell sequencing data. To our knowledge,
this has not been done before for single cell sequencing data
and we suggest that this should be incorporated in future
single sequencing experiments as this gives a better insight
in the read distribution in these experiments and to what ex-
tent reliable SNP calling can be performed. Finally, we have
presented our results in terms of maximum likelihood esti-
mate of allelic dropout p and find this value to be 0.60 ±
0.25.
The first commercial microfluidic device method for pro-
cessing single cells for sequencing18 was known to suffer sig-
nificantly from the capture of doublets rather than single
cells. Our approach has the advantage that we can take an
image of trapped cells to confirm the single cell occupancy of
each trap before proceeding to sequencing.
The more recently emerging droplet-based single cell flu-
idics and dilution tagging and pooling approaches offer the
highest throughput (up to 10 000 s of cells) compared to 10–
100 s of the microfluidic trapping approaches. However, an
advantage of our approach, is that it can be used to extract
and process RNA from the same cell as the DNA;7 such
multi-omic characterization will be important for making the
connection between genotype and molecular phenotype to
gain a better understanding of cellular mechanisms and to
better select the mutations that may be driving a cancer phe-
notype and which might be candidates for targeted therapy.
For such integrative omics applications it is important to
know that the comparative performance metrics of our single
cell processing devices are equivalent to other types of de-
vices and approaches. We can conclude that our DNA se-
quencing results show that the output of our device is at least
comparable to, if not better than the valve-based commercial
devices and offers advantages over non-microfluidic ap-
proaches such as a very low contamination level.
5 Conclusions
We have developed a passive microfluidic device for individu-
ally isolating cancer cells and extracting their single cell whole
genomes in sub-nanoliter volumes. The device is fabricated by
injection moulding, mounted in a prototype instrument and
used to prepare single cell DNA for pair-end Illumina sequenc-
ing. Using the sequencing metrics of more than 50 single
cells, we compare our data to previous studies where both ex-
traction and amplification steps are performed in nanoliter
volumes inside microfluidic devices. From the high coverage,
homogeneity and virtual elimination of contamination we ob-
tain with our device, we conclude that only the extraction step
needs to be done in sub-nanoliter volumes, while amplifica-
tion can be done in larger volumes with a conventional MDA
bench protocol. Since our device focuses on extracting DNA
from isolated cells only, it provides the flexibility of using any
DNA amplification protocol outside the device and reduces
the complexity of the device and instrumentation.
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